Next-Generation SERD Protects Against Progression in Some Patients with Advanced Breast Cancer Resistant to Standard Hormone Therapy
Next-Generation SERD Protects Against Progression in Some Patients with Advanced Breast Cancer Resistant to Standard Hormone Therapy

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer—as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib…